Valeo Pharma (CSE: VPH – OTCQB: VPHIF) CEO Steve Saviuk joined Steve Darling from Proactive with news the company has seen a strong launch of 3 new products which had helped the company achieve record-setting revenue for the second quarter.
Saviuk telling Proactive their existing portfolio along with 3 new products, including Redesca, helped the company report revenue of 2.65 million which was up 27% from the 2.1 million seen in Q2 2020. Saviuk also shared with Proactive the company has completed a financing with 11.5 million added to the treasury.